These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8857552)

  • 1. Erythromycin breath test and clinical transplantation.
    Watkins PB
    Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
    Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients.
    Turgeon DK; Leichtman AB; Lown KS; Normolle DP; Deeb GM; Merion RM; Watkins PB
    Clin Pharmacol Ther; 1994 Sep; 56(3):253-60. PubMed ID: 7924120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
    Watkins PB; Turgeon DK; Saenger P; Lown KS; Kolars JC; Hamilton T; Fishman K; Guzelian PS; Voorhees JJ
    Clin Pharmacol Ther; 1992 Sep; 52(3):265-73. PubMed ID: 1526083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients.
    Turgeon DK; Normolle DP; Leichtman AB; Annesley TM; Smith DE; Watkins PB
    Clin Pharmacol Ther; 1992 Nov; 52(5):471-8. PubMed ID: 1424421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
    Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
    Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
    Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
    Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
    Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
    Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
    Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of metronidazole on hepatic CYP3A4 activity.
    Haas CE; Kaufman DC; DiCenzo RC
    Pharmacotherapy; 2001 Oct; 21(10):1192-5. PubMed ID: 11601665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A4 and the erythromycin breath test.
    Wagner D
    Clin Pharmacol Ther; 1998 Jul; 64(1):129-30. PubMed ID: 9695728
    [No Abstract]   [Full Text] [Related]  

  • 12. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
    Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
    Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
    Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
    Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
    Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
    Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test.
    Tateishi T; Graham SG; Krivoruk Y; Wood AJ
    Br J Clin Pharmacol; 1995 Oct; 40(4):411-2. PubMed ID: 8554946
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of influenza immunization on CYP3A4 activity.
    Hayney MS; Hammes RJ; Fine JP; Bianco JA
    Vaccine; 2001 Dec; 20(5-6):858-61. PubMed ID: 11738750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.
    Gharaibeh MN; Gillen LP; Osborne B; Schwartz JI; Waldman SA
    J Clin Pharmacol; 1998 Jun; 38(6):492-5. PubMed ID: 9650537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the erythromycin breath test for use in cancer patients.
    Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
    Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease.
    Lown K; Kolars J; Turgeon K; Merion R; Wrighton SA; Watkins PB
    Clin Pharmacol Ther; 1992 Mar; 51(3):229-38. PubMed ID: 1544283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in activity of hepatic CYP3A4 in patients infected with HIV.
    Slain D; Pakyz A; Israel DS; Monroe S; Polk RE
    Pharmacotherapy; 2000 Aug; 20(8):898-907. PubMed ID: 10939550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.